Literature DB >> 20527995

Lafora disease: epidemiology, pathophysiology and management.

Thomas S Monaghan1, Norman Delanty.   

Abstract

Lafora disease is a rare, fatal, autosomal recessive, progressive myoclonic epilepsy. It may also be considered as a disorder of carbohydrate metabolism because of the formation of polyglucosan inclusion bodies in neural and other tissues due to abnormalities of the proteins laforin or malin. The condition is characterized by epilepsy, myoclonus and dementia. Diagnostic findings on MRI and neurophysiological testing are not definitive and biopsy or genetic studies may be required. Therapy in Lafora disease is currently limited to symptomatic management of the epilepsy, myoclonus and intercurrent complications. With a greater understanding of the pathophysiological processes involved, there is justified hope for future therapies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20527995     DOI: 10.2165/11319250-000000000-00000

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  122 in total

1.  Insights into Lafora disease: malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin.

Authors:  Matthew S Gentry; Carolyn A Worby; Jack E Dixon
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-01       Impact factor: 11.205

2.  Lafora bodies associated with neurologic signs in a cat.

Authors:  D G Hall; W L Steffens; L Lassiter
Journal:  Vet Pathol       Date:  1998-05       Impact factor: 2.221

3.  Isolation and characterization of mouse homologue for the human epilepsy gene, EPM2A.

Authors:  S Ganesh; K Amano; A V Delgado-Escueta; K Yamakawa
Journal:  Biochem Biophys Res Commun       Date:  1999-04-02       Impact factor: 3.575

4.  Short and long interval cortical inhibition in patients with Unverricht-Lundborg and Lafora body disease.

Authors:  Laura Canafoglia; Claudia Ciano; Elisa Visani; Paola Anversa; Ferruccio Panzica; Maurizio Viri; Elena Gennaro; Federico Zara; Francesca Madia; Silvana Franceschetti
Journal:  Epilepsy Res       Date:  2010-02-01       Impact factor: 3.045

5.  Fixation-sensitive myoclonus in Lafora disease.

Authors:  S Kumada; M Kubota; M Hayashi; A Uchiyama; K Kurata; Y Kagamihara
Journal:  Neurology       Date:  2006-05-23       Impact factor: 9.910

6.  MR spectroscopy findings in Lafora disease.

Authors:  Ebru Altindag; Batuhan Kara; Betul Baykan; Ege Terzibasioglu; Serra Sencer; Levent Onat; Mustafa Sirvanci
Journal:  J Neuroimaging       Date:  2008-11-14       Impact factor: 2.486

7.  [Non-convulsive epileptic status associated with Lafora disease: two case reports].

Authors:  E G Lopez-Meza; F Cerda-Tellez; I M Alanis-Guevara; M C Fernández González-Aragón; L A Ruano-Calderón
Journal:  Rev Neurol       Date:  2003 Nov 16-30       Impact factor: 0.870

8.  The malin-laforin complex suppresses the cellular toxicity of misfolded proteins by promoting their degradation through the ubiquitin-proteasome system.

Authors:  Punitee Garyali; Pratibha Siwach; Pankaj Kumar Singh; Rajat Puri; Shuchi Mittal; Sonali Sengupta; Rashmi Parihar; Subramaniam Ganesh
Journal:  Hum Mol Genet       Date:  2008-11-25       Impact factor: 6.150

9.  Arylsulfatase A pseudodeficiency and Lafora bodies in a patient with progressive myoclonic epilepsy.

Authors:  P Tinuper; G Plazzi; L Monari; S Sangiorgi; J F Pellissier; A Cerullo; F Provini; S Capellari; A Baruzzi; E Lugaresi
Journal:  Epilepsia       Date:  1994 Mar-Apr       Impact factor: 5.864

10.  Longitudinal EEG studies in a kindred with Lafora disease.

Authors:  C Yen; A Beydoun; I Drury
Journal:  Epilepsia       Date:  1991 Nov-Dec       Impact factor: 5.864

View more
  13 in total

Review 1.  Getting a handle on glycogen synthase - Its interaction with glycogenin.

Authors:  Elton Zeqiraj; Frank Sicheri
Journal:  Mol Aspects Med       Date:  2015-08-13

2.  A bioassay for Lafora disease and laforin glucan phosphatase activity.

Authors:  Amanda R Sherwood; Mary Beth Johnson; Antonio V Delgado-Escueta; Matthew S Gentry
Journal:  Clin Biochem       Date:  2013-09-06       Impact factor: 3.281

3.  Pharmacological Interventions to Ameliorate Neuropathological Symptoms in a Mouse Model of Lafora Disease.

Authors:  Arnaud Berthier; Miguel Payá; Ana M García-Cabrero; Maria Inmaculada Ballester; Miguel Heredia; José M Serratosa; Marina P Sánchez; Pascual Sanz
Journal:  Mol Neurobiol       Date:  2015-01-28       Impact factor: 5.590

4.  Homeostasis of the astrocytic glutamate transporter GLT-1 is altered in mouse models of Lafora disease.

Authors:  Carmen Muñoz-Ballester; Arnaud Berthier; Rosa Viana; Pascual Sanz
Journal:  Biochim Biophys Acta       Date:  2016-03-11

Review 5.  Links between autophagy and disorders of glycogen metabolism - Perspectives on pathogenesis and possible treatments.

Authors:  Benjamin L Farah; Paul M Yen; Dwight D Koeberl
Journal:  Mol Genet Metab       Date:  2019-11-21       Impact factor: 4.797

6.  Inflammation in Lafora Disease: Evolution with Disease Progression in Laforin and Malin Knock-out Mouse Models.

Authors:  Irene López-González; Rosa Viana; Pascual Sanz; Isidre Ferrer
Journal:  Mol Neurobiol       Date:  2016-04-04       Impact factor: 5.590

7.  Immunodeficiency, autoinflammation and amylopectinosis in humans with inherited HOIL-1 and LUBAC deficiency.

Authors:  Bertrand Boisson; Emmanuel Laplantine; Carolina Prando; Silvia Giliani; Elisabeth Israelsson; Zhaohui Xu; Avinash Abhyankar; Laura Israël; Giraldina Trevejo-Nunez; Dusan Bogunovic; Alma-Martina Cepika; Donna MacDuff; Maya Chrabieh; Marjorie Hubeau; Fanny Bajolle; Marianne Debré; Evelina Mazzolari; Donatella Vairo; Fabrice Agou; Herbert W Virgin; Xavier Bossuyt; Caroline Rambaud; Fabio Facchetti; Damien Bonnet; Pierre Quartier; Jean-Christophe Fournet; Virginia Pascual; Damien Chaussabel; Luigi D Notarangelo; Anne Puel; Alain Israël; Jean-Laurent Casanova; Capucine Picard
Journal:  Nat Immunol       Date:  2012-10-28       Impact factor: 25.606

8.  Dimerization of the glucan phosphatase laforin requires the participation of cysteine 329.

Authors:  Pablo Sánchez-Martín; Madushi Raththagala; Travis M Bridges; Satrio Husodo; Matthew S Gentry; Pascual Sanz; Carlos Romá-Mateo
Journal:  PLoS One       Date:  2013-07-26       Impact factor: 3.240

9.  Loss of GABAergic cortical neurons underlies the neuropathology of Lafora disease.

Authors:  Saida Ortolano; Irene Vieitez; Roberto Carlos Agis-Balboa; Carlos Spuch
Journal:  Mol Brain       Date:  2014-01-28       Impact factor: 4.041

10.  Progressive Myoclonic Epilepsy Due to Lafora Body Disease with a Novel Mutation.

Authors:  Anil V Israni; Anirban Mandal
Journal:  J Pediatr Neurosci       Date:  2018 Jan-Mar
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.